Dogan, Ayse Dudu Altintas http://orcid.org/0000-0001-6953-9969
Christensen, Thomas Quist
Jensen, Torben Tranborg
Juhl, Claus Bogh
Hilberg, Ole
Bladbjerg, Else-Marie
Hess, Søren
Funding for this research was provided by:
University of Southern Denmark
Article History
Received: 13 October 2023
Accepted: 5 June 2024
First Online: 20 June 2024
Declarations
:
: The trial was conducted in accordance with the declaration of Helsinki after approval by the Scientific Ethics Committee of The Region of Southern Denmark (j. no S-20170147) and Eudract (j. no. 2017-003551-32). The study was reported at clinicaltrials.gov (NCT03466021) and monitored according to Good Clinical Practice (GCP) by the GCP Unit of Odense University Hospital, Odense, Denmark. Informed consent was obtained from all individual participants included in the study
: N/A.
: CBJ serves as a speaker for Novo Nordisk, but has no financial interest in the current study. Study medication and running costs were provided by Novo Nordisk as a part of the Investigator Sponsored Studies Program. The authors have no relevant financial or non-financial interests to disclose.